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Prostate cancer (CaP) is the leading cancer among men of African descent in the USA, Caribbean, and Sub-Saharan Africa (SSA).
The estimated number of CaP deaths in SSA during 2008 was more than five times that among African Americans and is expected
to double in Africa by 2030. We summarize publicly available CaP data and collected data from the men of African descent
and Carcinoma of the Prostate (MADCaP) Consortium and the African Caribbean Cancer Consortium (AC3) to evaluate CaP
incidence and mortality in men of African descent worldwide. CaP incidence and mortality are highest in men of African descent
in the USA and the Caribbean. Tumor stage and grade were highest in SSA. We report a higher proportion of T1 stage prostate
tumors in countries with greater percent gross domestic product spent on health care and physicians per 100,000 persons. We also
observedthatregionswithahigherproportionofadvancedtumorsreportedlowermortalityrates.ThisfindingsuggeststhatCaPis
underdiagnosedand/orunderreportedinSSAmen.Nonetheless,CaPincidenceandmortalityrepresentasignificantpublichealth
problem in men of African descent around the world.
1. Introduction
LittleisknownabouttheepidemiologyofCaPamongmenin
Sub-Saharan Africa (SSA) [1]. However, men of SSA descent
around the world appear to suffer disproportionately from
CaP compared to men of other races or ethnicities [2].
The International Agency for Research on Cancer (IARC)
estimatesthatCaPistheleadingcancerintermsofincidence
and mortality in men from Africa and the Caribbean [3].
IARC also estimates that CaP is a growing problem in Africa
with approximately 28,006 deaths from CaP in 2010, and
approximately 57,048 deaths in 2030 [4]. This represents a
104% increase in the number of CaP deaths in Africa over
the next two decades. However, CaP incidence and mortality
rates that may be underestimated in SSA and possibly the
Caribbean were compared to USA rates due to lack of
screening,limitedpopulation-basedcancerregistrydata,and
underdiagnosis or treatment.
Comparisons of CaP incidence, prevalence, aggressive-
ness, and mortality in men of SSA descent are limited [5, 6].
Jackson et al. [7]reportedthattheage-adjustedincidencerate
in a combined West African (Accra and Ibadan) series (36.7
per 1000) was almost equal to the rate in the Washington,
DC series (40.6 per 1000). Although comparable prevalence
data for Senegal are not available, Gueye et al. [8]c o m p a r e d
clinical characteristics of CaP in African American (AA) and
Senegalese men diagnosed between 1997 and 2002. Tumor
stage was more advanced in Senegalese men than in AA
men.Thesedifferencesmayreflectsymptom-baseddiagnosis
in Senegal compared to diagnosis following elevated PSA
and/or positive digital rectal examination (DRE) in the USA.
A number of papers in African populations have character-
ized PSA levels, use of screening, and the relationship of PSA
withprostatetumorcharacteristics[9–13].Similardifferences
between prostate cancer characteristics among men in New
Y o r k ,G u y a n a ,a n dT r i n i d a dh a v eb e e nr e p o r t e dw i t hr e s p e c t
to tumor aggressiveness and survival [14]. These data suggest
that important differences by geography exist among men
of African descent and underscore the need for accurate
CaP data for Caribbean, SSA, and AA populations in order
to make meaningful comparisons. Insufficient population-
based cancer registration in SSA continues to be a barrier to
obtaining high quality data.
2. Methods
2.1. Sources of Incidence and Mortality Rates. The primary
data used for this report were derived from three sources.
First, age-adjusted African-American rates were obtained for
2008 incidence from the 17 registry SEER data set (SEER-17)
[15] and from 2008 mortality from national data [16]u s i n g
SEER
∗Stat software [17]. National estimates of the number
of cases were derived by multiplying the age-specific SEER-
17 incidence rates by the corresponding national population
estimates and summing over all age groups. For presentation
of incidence time trends, we used the 13 registry SEER
data set (SEER-13) [18] for the years 1992–2008. The USA
data were tabulated using SEER
∗Stat software [17]. Second,
estimated world incidence and mortality rates for the rest
of the world were obtained from GLOBOCAN 2008 [4].
As with SEER data, these rates were adjusted according
to the 1960 world standard. Third, a complete literature
review was undertaken to identify studies reporting CaP
rates in men of African descent by searching Medline for
the keywords “prostate cancer”, “African”, “Caribbean”, and
“Black.” Studies were initially not excluded based on sample
size, study design, or methodological quality. To maximize
comparability of studies across geography and/or time, stud-
ies were excluded if the ascertainment strategy or population
base from which the estimates were derived could not be
defined; estimates were based on hospital records, death
certificates, or other data sources deemed to be potentially
unreliable, or if rates were not age-standardized to the
1960 world population. All rates presented here were age-
standardized to the 1960 world population to be comparableProstate Cancer 3
with other reports of cancer incidence. Data for Africa
a n dt h eC a r i b b e a nf r o mG L O B O C A N2 0 0 8r e fl e c tt h et o t a l
population of the country or region being reported, and
therefore include men who are of non-African descent. The
proportionof men of non-Africandescent in each country or
r e g i o ni ss h o w ni nS u p p l e m e n t a r yT a b l e1a v a i l a b l eo n l i n ea t
http://dx.doi.org/10.1155/2013/560857 if known. To limit the
inferences to countries where the majority of the population
is of African descent, we excluded countries where <50%
of individuals were reported to be of African descent (e.g.,
Puerto Rico and Cuba).
2.2. Studies and Consortia. The men of African descent and
Carcinoma of the Prostate (MADCaP) consortium and the
African Caribbean Cancer Consortium (AC3) contributed
data to this report. The goal of these consortia is to develop
multicenter studies that address CaP research at a variety
of levels in men of SSA descent in North America, the
Caribbean, Europe, and Africa. MADCaP and AC3 studies
include epidemiological, biomarker, genetic, risk assessment,
and outcomes prediction research. Data regarding prostate
tumor characteristics were collected from the following
studies: the CAPGenes Prostate Cancer Genetics Studies
(CAPGenes) [19], Fred Hutchinson Cancer Research Center
(FHCRC) CaP Studies [20, 21] ,t h eP r o s t a t eC a n c e rR i s k
Assessment Program (PRAP) at Fox Chase Cancer Center
[22], the Flint Men’s Health Study (FMHS) [23, 24], Gene-
Environment Interaction in CaP (GECAP) Study at Henry
Ford Hospital [25], Los Angeles County Study (LACS) [26],
CaP Clinical Outcome Study (PC
2OS) at the University
of Louisville [27], MD Anderson Cancer Center [28], the
Multiethnic Cohort Study (MEC) [29],MoffittCancerCenter
Study [30], NCI Prostate Tissue Study (NCIPTS), University
of Pennsylvania Study of Cancer Outcomes, Risk, and Eth-
nicity (SCORE) [31], University of Texas San Antonio Center
forBiomarkersofRiskforCaP(SABOR),UniversityofTexas
H e a l t hSc i e n c eCe n t e ra tS a nA n t o n i o[ 32, 33], San Francisco
Bay Area Prostate Cancer Study (SFBAPCS) [34], United
Kingdom Genetic CaP Study (UKGPCS), and the Wake
UniversityConsortiumincludingparticipantsfromtheJohns
Hopkins University, Wake Forest University, and Washington
University (St. Louis) [35], the PROGRES (Prostate Gene-
tique Recherche Senegal) study in Dakar, Senegal [8, 36], the
Ghana Prostate Health Study (GPHS) in Accra, Ghana [37],
the Tygerberg Hospital study in Cape Town, South Africa
[38], the Guyana Tumor Registry [14], the Tobago Prostate
Cancer Screening Study [39], and unpublished data from the
B a h a m a sP r o s t a t eC a n c e rS t u d y .A ta l lM A D C a Pa n dA C 3
centers,datawerecollectedunderprotocolsapprovedbylocal
IRBs.
2.3. Assessment of CaP Ascertainment. Correlations between
percent T1 stage tumors and CaP incidence, mortality,
and population statistics on medical care were computed
using Spearman rank correlations, using abstracted literature
review and tumor stage data from the MADCaP consortium.
Sources of percent of gross domestic product spent on health
care outside the USA were obtained from WHO World
Health Statistics 2010 [42]. Comparable data for the USA
were obtained from the Centers for Medicare and Medicaid
Services by state [43]. STATA 10 was used for all descriptive
and statistical analyses of prostate tumor characteristics,
incidence, and mortality trends. All 𝑃 values are based on
two-sided testsat𝗼 =0.05. Statisticallysignificantdifferences
f r o mt h en u l lh y p o t h e s i sw e r ei n f e r r e da t𝑃 < 0.05.
3. Results
3.1. Recent Estimates of International Cancer Incidence and
Mortality. We estimated that more than 30,000 cases of
CaP were diagnosed among AA men in 2008 (Table 1). The
GLOBOCAN estimate for men in all of Africa in 2008 was
more than 39,000 CaP cases; the number in SSA would be
smaller,butwasnotestimated.Theestimatednumberamong
Caribbean men was half of the number in the USA or Africa.
CaP was by far the most frequently diagnosed reportable
cancer during 2008 in AA, Caribbean, and SSA men, with
the age-standardized CaP incidence rates ranging from 159.6
per 100,000 among AA to 71.1 in the Caribbean and 17.5 in
A f r i c a .Th e2 8 , 0 0 0d e a t h sd u et oC a Pi nA f r i c aw e r em o r e
thanfivetimesthe4,600amongAAandfourtimesthe6,500
among Caribbean men. The mortality rate for CaP exceeded
that for any other cancer in Africa (12.5 per 100,000) and
the Caribbean (26.3 per 100,000), and followed only lung
cancer among AA (22.4 versus 49.1 per 100,000). Whereas
the CaP incidence rate was highest among AA men, the CaP
mortality rate was highest in Caribbean men. Both the CaP
incidenceandmortalityrateswerelowerinAfricathaninAA
or Caribbean men. As a result, the mortality:incidence rate
ratiosrangedfrom0.71inAfricato0.41intheCaribbeanand
0.14 in AA.
3.2. International Variation in CaP Incidence. Figure 1 pre-
sents the age-standardized CaP incidence rates in men of
African descent from SSA, the Caribbean, and the USA
SEER program for various years 1990–2008. Supplementary
Table 1 presents the incidence rates and references for
the information plotted in Figure 1. Supplementary Table 2
presents rates that were not included in Figure 1 becausethey
represent estimates that were not standardized to the 1960
world population, did not reflect a clearly defined reference
population, were hospital or clinic-based, or for which the
sampling or ascertainment frame was not clearly defined.
Many of these rates vary widely, suggesting that they may not
be accurate. As shown in Figure 1 (and Supplementary Table
1), incidence rates in Africa historically have been <50 per
100,000, based on data from Uganda and Zimbabwe. Rates in
SEER-13 and SEER-17 cancer registries have all exceeded 150
per100,000,withapronouncedpeakat213.1during1993after
the introduction of widespread and adoption of PSA testing
and nadir at 163.4 during 2005.
During 2008, CaP incidence internationally was highest
in the USA Atlanta SEER registry (198.8 per 100,000) and
lowest in Niger (5.1 per 100,000), with substantial variability
by geography. Within the SEER-17 cancer registries, after
excluding two registries with <16 cases, rates ranged from
134.8 per 100,000 in Iowa to 198.8 per 100,000 in Atlanta. In4 Prostate Cancer
Table 1: Age-Standardized Estimates (ASE) of incidence and mortality during 2008 for five leading cancers in men of African descent by
Geography.
Location
Incidence
∗ Mortality
∗ Prostate Cancer
Mortality:incidence rate
ratio Cancer Number of cases ASE
∗∗ Cancer Number of deaths ASE
∗∗
Africa
Prostate 39,460 17.5 Prostate 28,006 12.5 0.71
Liver 34,612 11.7 Liver 33,826 11.7
Lung 20,821 8.4 Lung 19,429 7.9
Colorectal 19,049 6.9 Esophagus 16,678 6.5
Bladder 16,938 6.7 Colorectal 14,707 5.5
Caribbean
Prostate 15,950 71.1 Prostate 6,543 26.3 0.41
Lung 5,555 25.7 Lung 5,157 23.6
Colorectal 3,186 14.4 Colorectal 2,010 8.8
Stomach 2,418 11.2 Stomach 1,769 8.0
Larynx 1,469 7.1 Liver 1,304 6.1
US
(African
American)
Prostate 30,068 159.6 Lung 9,629 49.1
Lung 11,712 60.4 Prostate 4,587 22.4 0.14
Colorectal 8,298 42.0 Colorectal 3,478 17.5
Kidney 3,600 18.2 Pancreas 1,894 9.6
Bladder 2,415 12.2 Liver 1,748 8.7
∗
African and Caribbean incidence and mortality estimates from GLOBOCAN 2008 and include men of all races. US incidence rates from SEER-17, estimated
numbers of cases for the total US based on the SEER-17 rates, and US mortality data for the entire country; all include only African American men.
∗∗ASE: Age-Standardized Estimates per 100,000 population adjusted to the 1960 world population.
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Figure 1: Estimates of CaP incidence (1990–2008) per 100,000 men
of African descent, age-standardized to the 1960 world Population.
Incidence rates for the USA are from SEER-13 for 1992–2008;
data for 2008 include one estimate from each of the SEER-17
registries, except two registries with <16 cases. Incidence rates for
allCaribbeancountriesarefrom2008GLOBOCANdata.Incidence
rates for African countries are from specific population-based
cancer registries for 1990–2004 and from 2008 GLOBOCAN data.
Rates can be found in Supplementary Table 1. Incidence rates are
age-standardized to the 1960 world population.
theCaribbean,ratesvariedfrom51.1per100,000inJamaicato
173.7 per 100,000 in Martinique. In SSA, incidence rates were
generally lower than those in the USA or Caribbean varying
from 5.1 per 100,000 in Niger to 59.7 per 100,000 in South
Africa.
3.3. International Variation in CaP Aggressiveness. Table 2
reports characteristics of prostate tumors in Africa, the
C a r i b b e a n ,t h eU K ,a n dt h eU S Ab a s e do nl i t e r a t u r er e v i e w
a n dd a t af r o mt h eM A D C a PC o n s o r t i u m .Th e s ed a t ar e p -
resent clinical data from observational (e.g., cohort, case-
control, or population-based screening) studies, and there-
fore may not represent the distribution of traits in the
population as a whole. In addition, some studies have pref-
erentiallyascertainedadvanceddisease,hospital-basedcases,
or population-based cases. Some imposed age restrictions on
case ascertainment. Therefore, the proportions reported here
reflect not only geographic differences but also differences in
study design. The proportion of tumors that were T1 stage
in AA men ranged from 35–63%, compared with 15–29% in
S S A ,a n d2 4 %i nt h eC a r i b b e a na n d3 4 %i nt h eU K .Th e r e
were significant differences in Gleason score (𝑃 = 0.003),
tumor stage (𝑃 < 0.001), and PSA levels at diagnosis (𝑃<
0.0001) between USA, UK, and African studies. A signifi-
cantly greater proportion of tumors in Africa had a high
Gleason score or high tumor stage compared with those in
the USA or UK. In the UK and USA, the most common
Gleason scores are 6 and 7, whereas the distribution in other
regions is more uniform, with lower (≤5) and higher (≥8)
scores representing a greater proportion of tumors than inProstate Cancer 5
Table 2: International variation in prostate tumor characteristics in men of African descent.
Region Location
Data
source
∗ 𝑁
Mean age at
diagnosis (Yrs,
range)
Median PSA
(ng/mL, range)
Gleason score, % Tumor stage, %
≤5 6 7 8 9+ T1 T2 T3 T4
Africa
Dakar, Senegal HBCC 114 68 (41–95) 59.5 (0.5–6,190) 39 18 19 20 4 19 35 30 16
Accra, Ghana PSS 689 69 (42–95) 52.0 (0.7–8,423) 68 12 8 6 6 15 42 21 22
Cape Town,
South Africa:
Coloured
HBCC 207 67 (46–94) 19.3 (0.5–14,390) 20 31 21 12 16 29 30 19 22
Cape Town,
South Africa:
Black
HBCC 23 70 (52–90) 37.2 (5–3,308) 22 11 11 33 22 25 20 25 30
Caribbean
Guyana HBCS 169 74 (26–98) NA NA NA NA NA NA 91 (T1 + T2) 4 5
Jamaica [40] HBCS 529 71 (41–91) 30.7 (12–109) 13 7 3 2 1 91 1 N AN AN A N A
Jamaica [41] HBCS 99 72 (50–90) 37.0 (1–2,100) 01 6 2 4 4 11 8 2 4 3 9 2 19
Tobago PBR 508 65 (40–79) 6.3 (0.3–18,330) .5 46 41 6 6 NA NA NA NA
UK Greater London HBCS 177 71 (48–87) 107.6 (1–2,463) 10 40 38 9 3 34 42 20 4
US
Northeast
∗∗ HBCC 879 59 (36–88) 5.9 (0.3–69) 2 51 40 5 3 38 35 27 0.6
Southeast
∗∗ HBCC 727 61 (91.36) 6.4 (0–5,000) 8 36 37 8 10 35 51 13 0.6
Midwest
∗∗ HBCC 533 69 (38–97) 7.0 (0–14,635) 22 4 5 41 01 06 3 3 2 5 0
West
∗∗
PBCC,
PCS,
HRCC
1,474 74 (42–91) NA 7 30 40 15 7 89 (T1 + T2) 10 0.5
∗
Studytype:HBCC:hospital-basedcase-control;HBCS:hospital-basedcaseseries;HRCC:highrisk(aggressivedisease)case-controlstudy;PBCC:population-
based case-control; PBR: population-based cancer registry; PCS: prospective cohort study; PSS: population screening study.
∗∗MADCaP Groups: Northeast: Philadelphia, Baltimore, Washington DC; Southeast: Louisville, Houston, San Antonio, Tampa, Wake Forest; Midwest:
Cleveland,Detroit,Flint,St.Louis;West:Seattle,LosAngeles,SanFranciscoBayArea.Datafromothercentersasdescribedinmethods;citations indicatedata
were taken from the literature only; NA: Not Available.
the USA. The tumor stage distribution differed substantially
by geography, with a larger proportionof stage T3/T4 tumors
in Africa than other locations. PSA levels at diagnosis were
lowest in the USA and Tobago. There were no statistically
significant differences in Gleason score (𝑃 = 0.07), tumor
stage (𝑃 = 0.51), or PSA at diagnosis (𝑃 = 0.24)a m o n g
centers within Africa.
3.4. International Variation in CaP-Specific Mortality. Table 1
suggested that the CaP ratio of mortality to incidence in
Africa (0.71) is notably higher than that in the Caribbean
(0.41) or AA men (0.14). To further explore mortality rates
in these regions, Figure 2 presents CaP mortality rates (stan-
dardized to the 1960 world population) in men of African
d e s c e n ti nt h eU S A ,S S A ,a n dt h eC a r i b b e a n .Th em o r t a l i t y
estimates vary considerably and overlap across regions. In
the Caribbean, CaP mortality rates were comparable to or
higher than in AA men. For example, the total AA mortality
rate was 22.4 per 100,000 compared with estimates as high
as 61.7 per 100,000 in Barbados [44], which was the highest
reported in the world. In SSA, estimated mortality rates
were generally lower than those in the USA or Caribbean.
Mortality estimates in 2008 ranged from a low of 4.4 per
100,000 in Niger to 28.8 per 100,000 in Cote d’Ivoire [44].
Indeed some rates in AA were lower than several in Africa
and many in the Caribbean. As shown in Table 2,t h e
proportionwithhighstage/gradediseaseatdiagnosisismuch
g r e a t e ri nA f r i c at h a ni nA A .
3.5. Completeness of CaP Ascertainment. Figure 3 presents
the relationship of the proportion of tumors diagnosed at T1
s t a g e ,b a s e do nd a t af r o mt h eM A D C A Pc o n s o r t i u m ,w i t h
characteristicsthatmayberelatedtoCaPdetection:CaPinci-
dence, based on cancer registry data (Figure 3(a)), percent
of gross domestic national or state product spent on health
care(Figure 3(b)),andnationalorstatenumberofphysicians
per 10,000 persons (Figure 3(c)) .A ss h o w ni nF i g u r e s3(a)–
3(c), there was a strong positive correlation between each
of these variables and percent of tumors diagnosed at T1
stage. Figure 3(d) also presents the relationship of T1 stage
tumors by CaP mortality in SSA, the Caribbean, and several
USAstatesforwhichT1stagedatawereavailable.Figure 3(d)
suggests that the higher the proportion of T1 stage tumors
diagnosed, the higher the mortality rate. Stated differently,
mortality rates are lower in SSA and the Caribbean, where T1
s t a g et u m o r sa r el e a s tl i k e l yt ob ed i a g n o s e d .H o w e v e r ,g i v e n
that the mortality:incidence rate ratio (Table 1)o fc a n c e r si n
Africa(0.71)andtheCaribbean(0.41)aresubstantiallyhigher
than in the USA (0.14), these results suggest that there is a
substantial underreporting of cases of CaP in at least some
parts of SSA and the Caribbean.
4. Discussion
Our data suggest that among men of Africa descent, CaP is
most common in AA and Caribbean men, and considerably
less common in SSA (Figure 1). These data also suggest that6 Prostate Cancer
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Figure 2: Estimates of 2008 CaP mortality per 100,000 men, age-standardized to the 1960 world population. African American data are
from states with at least one SEER-17 cancer registry (excluding states with fewer than 10 CaP deaths), African and Caribbean data are from
GLOBOCAN 2008.
CaP is a major cancer in men of African descent throughout
the world, and that the currently available incidence and
mortality rates may represent an underestimate of the actual
CaP incidence and mortality rates in SSA and the Caribbean.
DespitetheevidencethatCaPoccursathighratesinAAmen,
relatively little data are available regarding the epidemiology
of CaP in men of African descent in other locations. Possible
explanations for the wide range in CaP incidence and mor-
tality by geography observed here fall into several categories:
(1) differences inhealthcareaccess, diagnosis,andscreening;
(2) differences in the methodology used to generate rates
including completeness of ascertainment and (3) underlying
differences in risk due to demographic differences, genet-
ics/biology, lifestyle, or environmental exposures.Prostate Cancer 7
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Figure 3: Relationship of prostate tumor aggressiveness with CaP incidence, mortality, and health care-related statistics in men of
African descent. % T1 stage tumor data from the MADCaP and AC3 Consortia. (a) Percent of tumors diagnosed at T1 stage by PCa
incidence (per 100,000 population). Age-standardized incidence rates from 2008 GLOBOCAN and 2008 SEER-17 cancer registries (San
Francisco-Oakland, San Jose/Monterey, and Los Angeles, California; Connecticut; Detroit; Louisiana; New Jersey). (b) Percent of tumors
diagnosed at T1 stage by percent of gross domestic product spent on health Care. Sources of percent of gross domestic product spent
on health care: (1) Outside USA: WHO World Health Statistics 2010 (http://www.who.int/whosis/whostat/EN WHS10 Full.pdf); (2) USA:
Centers for Medicare and Medicaid Services (https://www.cms.gov) by state. (c) Percent of tumors diagnosed at T1 stage by number of
physicians per 10,000 persons. Sources of data on physicians per 10,000 persons: (1) Outside USA: WHO World Health Statistics 2010
(http://www.who.int/whosis/whostat/EN WHS10 Full.pdf); (2) USA (by state): Dionne, M., Moore, J., Armstrong, D., Martiniano, R. (2006)
The United States health workforce profile. Rensselaer, NY: Center for Health Workforce Studies, School of Public Health, SUNY Albany. (d)
percent of tumors diagnosed at T1 stage by CaP mortality (per 100,000 population). Mortality data for 2006 from CDC Wonder Database
(http://wonder.cdc.gov/).
4.1. Health Care Access and Screening. PSA is widely used
in the USA for detection of CaP. While PSA improves CaP
detection beyond digital rectal examination (DRE) [45], its
sensitivity and specificity are suboptimal, and it has not
been widely implemented in clinical practice in many parts
of the world. PSA testing is responsible for a sharp peak
in the incidence of prostate tumors detected in the USA
and other countries between 1990–1995, but the additional
cases detected during this period were primarily localized
disease [46]. Many of these tumors may not have been
diagnosed until later, if at all, or until they caused clinically
relevant events had PSA testing not been in use [47]. Data
regardingscreeningpracticesandrates,aswellastimetrends
in mortality, are not widely available for African descent
populations outside the USA.
The use of PSA testing impacts the international com-
parisons made here. While the prevalence of PSA testing is
not well documented, it appears that CaP is also commonly8 Prostate Cancer
detected when PSA testing is performed in Caribbean men
[39]. No data exist regarding the prevalence of PSA usage in
Africa, but it is believed that PSA testing is not common.
Thus, lower rates of CaP in Africa may in part reflect
lower probability of CaP detection than in countries like the
USA where PSA and DRE screening are more widely used.
Compounding the lower use of PSA testing is issues related
to access to cancer-related health care, including diagnosis
and treatment of disease. There are currently no data on the
proportionofCaP thatisneverdiagnosedina clinical setting
in Africa.
4.2. Methodological Issues in Estimating CaP Incidence and
Mortality. Limitations in the availability of data in some
regions limit our ability to make strong inferences about the
actualratesofCaPinsomecountriesandtomakevalidcom-
parisons of these rates across countries. Direct comparisons
of rates globally are limited by a number of methodological
issues.Differentagestandardizationsmaybeusedindifferent
studies. All data presented here present age-standardized
rates standardized to the 1960 world population to maximize
comparability. Limitations in available data also preclude
strong inferences and comparisons of international rates.
In many countries, incidence and mortality rates do not
separate out men of African descent from men of other
ethnicities. For example, the available data in the Caribbean
and Africa represent all men, regardless of race. Thus, the
rates of CaP reported here are meant to reflect those in men
of African descent, but in fact they represent the rates for
all men in these countries (aside from the countries we have
omitted where the proportion of African descent men was
low). We have presented data obtained from population-
based cancer registries (Supplementary Table 1), but many
r e p o r t sr e l yo nd a t ao b t a i n e df r o mh o s p i t a l - b a s e do ro t h e r
ascertainment strategies that may not reflect CaP cases in
the general population (Supplementary Table 2), or may
compriseabiasedsubsetofcases.Thus,somereportssuggest
very low or very high rates of CaP, but it is not clear whether
t h e s er e p o r t sa r ev a l i da n dt h e ym a yn o tb eu s e f u li nm a k i n g
internationalcomparisons.Wehavealsonotpresenteddirect
comparisons of rates across populations because data were
not available to obtain meaningfulvarianceestimates around
incidence or mortality rates across populations. However, to
the degree that the rates reflect the correct population esti-
matesbasedonlargesamples,𝑃valuesmaynotberequiredto
compare relative rates across populations. Similarly, reports
of mortalityin Africa are captured by variousmeans, and the
accuracyofcauseofdeathreportsinadditiontocompleteness
of reporting may be inadequate. Therefore, comparisons of
USA,Caribbean,andSSArates maybe limitedby differences
in data reporting across regions.
4.3.UnderlyingRiskProfileDifferences. At least two hypothe-
ses can be proposed to explain differences in CaP risk
across populations of African descent. First, it is possible
that CaP is underdiagnosed in the less developed world,
particularly in SSA, and the rates are in fact higher than is
suggested by existing data due to limited tumor detection.
This hypothesis is addressed below. Second, it is possible that
CaP incidence is truly lower in the developing world than in
the developed world. This might imply that SSA populations
are less susceptible to CaP due to genetic risk, environmental
exposures, or other risk factors that cause CaP. Differences
in life expectancy in developed countries versus Africa may
influence CaP rates. Differences in underlying risk profiles
across populations may also explain in part differences in
risk across populations. Recent studies have identified a large
number of loci that are involved in CaP susceptibility, and
thereisgrowingevidencethatthefrequencyandcontribution
of these risk alleles to CaP differ across populations. Chang
et al. [48] reported the multicenter MADCaP study of CaP
susceptibility using a sample of nearly 8000 men of African
descent in the USA and UK. They reported that the majority
o ft h el o c ii d e n t i fi e da sC a Ps u s c e p t i b i l i t yl o c ii nW h i t eo r
A s i a np o p u l a t i o n sw e r en o tr e p l i c a t e di nm e no fA f r i c a n
descent. Haiman et al. [49] reported a genome-wide asso-
ciation study (GWAS) using a sample of over 6000 African
descent CaP cases and controls that overlapped with the
sample of Chang. This GWAS also did not replicate most of
the previously reported loci identified in European or Asian
descent populations [50]. Haiman et al. [49] also identified a
novel locus on chromosome 17 that had not been identified
in prior GWAS. The risk variant at this new locus was only
identifiedinAfricandescentpopulationsandwasnotpresent
in European descent populations. Explanations for the lack
of replication across racial groups include the possibility that
the underlying genetic etiology of CaP differs across racial
groups,andthatthefrequencyofriskallelesindifferentpop-
ulationsissufficientlyvariablethattheeffectsofthesevariants
cannot be detected in some groups. Finally, it is possible
that genetic effects are dependent on nongenetic exposures,
such that the main effect of a locus differs depending on the
environmental context in which it is acting. Given the major
differences in environmental exposures, including infection
andlifestyleacrosspopulations,thisisalikelyhypothesisthat
requires additional study.
Even though environment can be hypothesized to play
a major role in CaP risk, there have been few consistent
exposures identified to date that are clearly associated with
CaP risk. The only epidemiological factors that are uncon-
tested are family history of prostate cancer, age, and race.
Therefore,itcannotbeclearlydeterminedthatenvironmental
exposuredifferencesacrosspopulationsexplaindifferentCaP
rates given that the role of these exposures on risk remains
unclear.
4.4. Is There Evidence for Underascertainment of CaP in Some
Populations? Our data suggest that CaP rates may be under-
estimated in SSA and possibly the Caribbean. This under-
ascertainment may be due to CaP underdiagnosis, under-
ascertainment, or both. It is not possible using the data
available here to distinguish these possible explanations for a
potential underestimation of CaP. We evaluated the relation-
ship of early stage tumors (i.e., stage T1) with characteristics
of the populations in which CaP is diagnosed (Figure 3).
Early stage tumors were strongly correlated with higherProstate Cancer 9
incidence, greater percent of gross domestic product spent
o nh e a l t hc a r e ,a n dg r e a t e rn u m b e ro fp h y s i c i a n sp e rp o p u -
lation. While certainly not conclusive, these data support the
hypothesis that countries where greater medical intervention
and access to health care are available have higher rates of
early stage prostate tumors. This finding is not surprising
but is consistent with the hypothesis that CaP incidence
rates in SSA are underestimated. However, it is critical to
remember that small numbers of cases, usually obtained
from clinic- or hospital-based series, may reflect relatively
less stable or representative information than those obtained
from population-based cancer registries (e.g., SEER) in the
developed world.
Evaluation of the variability in CaP rates is severely
limited by the availability of appropriate cancer registries in
SSA. According to IARC, approximately 38 cancer registries
were active in SSA in 2011, but only two of these were fully
compliant with IARC standards. One reason often cited for
the lack of compliance with IARC standards is that registries
may not have access to all newly diagnosed cancer cases in
the population and cannot provide pathology confirmation
of diagnoses due to limited pathology resources in many
countries. Evaluation of the accuracy of cancer incidence
rates obtained from population-based cancer registries in
Africa has been assessed in Uganda [51]. The evidence from
that assessment suggests accurate cancer rates can be
obtained in Africa if standardized protocols are followed.
Thus,additionalpopulation-basedcancerregistriesshouldbe
developedusingacceptedprotocolsinSSAtoobtainaccurate
estimates of cancer incidence and mortality.
In addition to limitations in the estimates of incidence
and mortality from population registries, it is not currently
possible to make global comparisons of differences among
these rates using available methods. While it is possible
to estimate variances and standard errors around the rates
of interest when observed counts are available (e.g., SEER
data), the standard in the field is to not estimate variances
for GLOBOCAN type estimates because they are based
around estimated counts, not actual observed counts. While
f o r m u l a ee x i s tt h a tc o u l db eu s e dt oe s t i m a t ev a r i a n t s ,t h e s e
a r eu n l i k e l yt ob ea c c u r a t eb e c a u s et h e r ea r em a n ys o u r c e s
of uncertainty and many assumptions made in the GLOBO-
CAN estimation process. Ferlay et al. [52]r e p o r tt h a tt h e
some necessary assumptions for variance estimation could
be quantified, whereas for others they clearly could not be.
Thus, it is not possible with current methodology to obtain
a single variance estimate that is appropriate for data from
all locations. Since it is not acceptable to make comparisons
of rates across different locations based around inaccurate
variance estimates, we do not estimate variances, nor do
we make direct comparisons of differences in rates across
populations.
Although we advocate for improved reporting of cancer
data to facilitate research and clinical practice, we are aware
that there have been concerns about the overdiagnosis of
CaP. Therefore, we do not advocate increased use of PSA
screening in SSA, but to develop appropriate approaches to
CaP screening in SSA that will limit CaP-related morbidity
and mortality.
5. Conclusions
CaP is estimated to be the most common tumor in SSA and
Caribbean men. However, accurate estimates of CaP inci-
dence and mortality, particularly in SSA, do not adequately
inform appropriate CaP screening and clinical practice. The
data presented here do not provide specific guidance about
optimal prostate cancer screening or treatment strategies in
Africa. However, it is likely that African-specific risk profiles,
disease aggressiveness, and health care access mean that
screening and treatment strategies may be different in Africa
than those in standard practice in North America or Europe.
IfCaPisactuallymorecommonthaniscurrentlyunderstood
in African descent populations, then CaP incidence rates
a r el i k e l yt ob eh i g h e ra n dm a yr e p r e s e n ta ne v e ng r e a t e r
public health problem than is currently thought. Additional
attention to the problem of CaP in Africa is warranted that
could include development of epidemiological research and
resources (e.g., high quality population-based cancer reg-
istries) to improve our understanding of the CaP burden in
African populations; epidemiological and genetics research
to understand the risk factors acting in Africa; studies to
determine appropriate use of PSA testing; and treatment-
related research that will lead to reduced CaP morbidity and
mortality in the Caribbean and SSA.
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